Radboudumc, Nijmegen, The Netherlands (RUMC), is an academic hospital whose mission is to have a significant impact on healthcare, by providing excellent patient care, education and top research. RUMC has organized its research into three research institutes. The department of Pharmacology-Toxicology is embedded in the Radboud Institute for Molecular Life Sciences (RIMLS) and Radboud Institute for Health Sciences (RIHS). In house technology centres offer state-of-the art facilities and are part of the Dutch Large Scale Scientific Infrastructure (http://www.onderzoeksfaciliteiten.nl/).
The Department of Pharmacology-Toxicology has extensive expertise in translational pharmacology including drug metabolism, drug transporter and pharmacogenomic studies, PK and PBPK modelling, microdosing studies, as well as translational clinical research. In addition to expertise in adult pharmacology, both paediatric and perinatal pharmacology expertise is present.
RUMC contributes to WP7 which aims to identify research infrastructure for paediatric pharmacology, and to WP5 (biomarker development), based on expertise on biomarker development in pain/sedation and acute kidney injury.
Main tasks in the project:
RUMC will contribute to WP7 which aims to identify research infrastructure for paediatric pharmacology PK-PD with the expertise and European Network in developmental pharmacology, pharmacogenomics, microdosing, perinatology, including placental transfer, PBPK modelling. RUMC contributes to WP7 by combining this expertise to contribute to building infrastructure for the specific paediatric expertise. RUMC will also contribute to WP5 (biomarker development), based on expertise and research network on biomarker development in pain/sedation and acute kidney injury. It will work also in WP2, WP3, WP8, WP9.